IDT Expands into Europe
News Oct 31, 2007
Integrated DNA Technologies (IDT) has announced further growth to its product range at its wholly-owned European subsidiary IDT, BVBA. This, coupled with an updated Euro based ordering system, is enabling IDT to better serve the broad variety of life science research projects in Europe.
According to Company, it has developed an unparalleled range of products and services placing it as the ‘No. 1’ supplier of custom oligonucleotides in the United States; they are now aiming to repeat this success in Europe.
Bonnie Barney, Senior Vice President European Sales/Global Advertising for IDT commented, “We have put a lot of time and effort into preparing for this exciting move.” She continued, “Europe presents us with the opportunity to further perfect our service offering as well as bring our extensive experience and product range within reach of more researchers.
”IDT have established a wholly-owned European subsidiary (IDT, BVBA) and is developing a new production facility, both situated in Leuven, Belgium. IDT, BVBA has a growing sales and support network; recent appointments covering the UK and mainland Europe.
As genome editing technologies advance toward clinical therapies, they are raising hopes of a completely new way to treat disease. However, challenges need to be addressed before potential treatments can be widely used in patients. To tackle these challenges, the National Institutes of Health has launched the Somatic Cell Genome Editing program, which has awarded multiple grants including more than $3.6 million to assess the safety of genome editing in human cells and tissues.